Literature DB >> 17515829

Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple.

Fernando P Polack1.   

Abstract

Atypical measles and enhanced respiratory syncytial virus disease (ERD) were serious diseases that resulted from exposure of children immunized with inactivated vaccines against measles virus (MV) and respiratory syncytial virus (RSV) to the respective wild-type agents in the 1960s. Although the clinical manifestations of both illnesses were different, the immune responses elicited and primed for by the vaccines shared important similarities. Both vaccines failed to elicit long-lived protective antibody and to promote cytotoxic T lymphocyte responses. In both cases, postvaccination exposure to wild type virus during community outbreaks was associated with immune complex deposition in affected tissues, vigorous CD4 T lymphocyte proliferative responses, and a Th2 bias of the immune response. No relapses of atypical measles or ERD were ever reported. In this manuscript, the pathogeneses of both enhanced diseases and the requirements for the generation of protective antibodies against MV and RSV are discussed, to contribute to the development of newer safe and effective vaccines against these important pathogens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17515829     DOI: 10.1203/PDR.0b013e3180686ce0

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  35 in total

1.  A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.

Authors:  Meagan Bolles; Damon Deming; Kristin Long; Sudhakar Agnihothram; Alan Whitmore; Martin Ferris; William Funkhouser; Lisa Gralinski; Allison Totura; Mark Heise; Ralph S Baric
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 2.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

3.  A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.

Authors:  Kenta Matsuda; Stephen A Migueles; Jinghe Huang; Lyuba Bolkhovitinov; Sarah Stuccio; Trevor Griesman; Alyssa A Pullano; Byong H Kang; Elise Ishida; Matthew Zimmerman; Neena Kashyap; Kelly M Martins; Daniel Stadlbauer; Jessica Pederson; Andy Patamawenu; Nathaniel Wright; Tulley Shofner; Sean Evans; C Jason Liang; Julián Candia; Angelique Biancotto; Giovanna Fantoni; April Poole; Jon Smith; Jeff Alexander; Marc Gurwith; Florian Krammer; Mark Connors
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 4.  Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.

Authors:  Barney S Graham
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 5.  Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.

Authors:  Von Vergel L Torres; Carrie F Coggon; Timothy J Wells
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

6.  Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine.

Authors:  Benjamin K Quintel; Archana Thomas; Danae E Poer DeRaad; Mark K Slifka; Ian J Amanna
Journal:  Vaccine       Date:  2018-12-31       Impact factor: 3.641

7.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.

Authors:  Mario Lobigs; Megan Pavy; Roy A Hall; Päivi Lobigs; Peter Cooper; Tomoyoshi Komiya; Hiroko Toriniwa; Nikolai Petrovsky
Journal:  J Gen Virol       Date:  2010-02-03       Impact factor: 3.891

8.  Vaccines against respiratory syncytial virus: The time has finally come.

Authors:  Barney S Graham
Journal:  Vaccine       Date:  2016-05-13       Impact factor: 3.641

9.  Immunopathogenesis Versus Protection in Dengue Virus Infections.

Authors:  Alan L Rothman; Carey L Medin; Heather Friberg; Jeffrey R Currier
Journal:  Curr Trop Med Rep       Date:  2014-03-01

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.